We recently demonstrated the pivotal role of the transcription factor (TF) activating TF 3 (ATF3) in dampening infl ammation. We demonstrate that ATF3 also ameliorates allergeninduced airway infl ammation and hyperresponsiveness in a mouse model of human asthma. ATF3 expression was increased in the lungs of mice challenged with ovalbumin allergen, and this was associated with its recruitment to the promoters of genes encoding Th2-associated cytokines. ATF3-defi cient mice developed signifi cantly increased airway hyperresponsiveness, pulmonary eosinophilia, and enhanced chemokine and Th2 cytokine responses in lung tissue and in lung-derived CD4 + lymphocytes. Although several TFs have been associated with enhanced infl ammatory responses in the lung, ATF3 attenuates the infl ammatory responses associated with allergic airway disease.
Asthma is a complex infl ammatory syndrome that aff ects > 10% of the North American population. The worldwide prevalence, morbidity, and mortality of asthma have signifi cantly increased over the last three decades ( 1 ) . Asthma is a chronic infl ammatory disease of the small airways that is characterized by mast cell, eosinophil, and mononuclear cell infi ltration of the submucosa along with goblet cell hyperplasia. The infl ammatory response in asthma is tightly associated with airway hyperresponsiveness to antigen-specifi c and nonspecifi c stimuli ( 2 ) . In humans, and in a mouse model, CD4 + Th2 cells play a crucial role in orchestrating airway infl ammation by producing IL4, IL5, and IL13 and by regulating the production of IgE and the growth and diff erentiation of mast cells and eosinophils ( 3, 4 ) . Although the role of cytokines in the asthmatic response is relatively well understood, little is known about the transcriptional regulation of these mediators in asthma ( 5, 6 ) .
The transcription factor (TF) NF-B regulates many facets of the infl ammatory response and also appears ( 7, 8 ) to have a role in the pathogenesis of asthma. For example, activated NF-B has been identifi ed in the airways of patients with asthma, and agents that exacerbate asthma such as allergens, ozone, and viral infections also stimulate NF-B ( 9 ) . Furthermore, corticosteroids, the fi rst-line treatment for asthma, are potent inhibitors of NF-B activation ( 10 ) . Finally, mice that are null for the p50 or c-Rel subunits of NF-B develop signifi cantly less airway infl ammation after allergen challenge ( 11 ) . We recently identifi ed activating TF 3 (ATF3) as a potent negative regulator of the infl ammatory response in macrophages ( 12 ) , where it antagonized NF-B -induced responses. ATF3 is a member of the CREB family of BZip (basic leucine zipper) transcription factors ( 13 ) . Its role in dampening infl ammation and its capacity to antagonize NF-B -induced responses prompted us to examine its role in a mouse model of human asthma ( 12 ) .
RESULTS

ATF3 is induced in a mouse asthma model
OVA sensitization and challenge led to a signifi cant increase in ATF3 transcription in the lungs of WT mice ( Fig. 1 A ) , and this was paralleled by increased expression of the protein ( Fig. 1 B ) . Immunohistochemical localization showed weak ATF3 staining in the epithelium of saline-treated WT mice. Upon treatment 1.00 ± 0.24; and ATF3-OVA, 1.19 ± 0.34). Airway resistance was signifi cantly increased in the OVA-treated ATF3-null mice when compared with their WT counterparts ( Fig.  2 A ) . The increased airway resistance in ATF3-null mice was accompanied by a fi vefold increase in infl ammatory cells in bronchoalveolar lavage (BAL) fl uid ( Fig. 2 B ) , whereas there was only a twofold increase in the cellular infl ux in WT BAL fl uid ( Fig. 2 B ) . Diff erential counts showed a signifi cantly higher number of macrophages, lymphocytes, and eosinophils in the BAL fl uid of ATF3-null mice ( Fig. 2 C ) . Remarkably, there was a 4.7-fold increase in pulmonary eosinophils ( Fig.  2 C ) . Histological analysis of lung tissue from OVA-treated WT mice showed an accumulation of eosinophils and mononuclear cells in the peribronchial and perivascular regions and edema of the airway interstitium compared with saline controls ( Fig. 2 D ) . Each of these features was markedly increased in OVA-treated ATF3-null mice. Signifi cantly, there was a dramatic increase in infl ammatory cell infi ltrate in the alveolar spaces of ATF3-null mice when compared with WT mice ( Fig. 2 D ) . Airway mucus production, as determined by periodic acid-Schiff staining, was similar between WT and ATF3-null mice under baseline conditions. However, goblet cell hyperplasia and mucous hypersecretion were more pronounced in allergic ATF3-null mice ( Fig. 2 D ) .
Effect of ATF3 defi ciency on Th2 responses
A hallmark of asthma is a skewed Th2-type immune response ( 4 ) . Lungs from OVA-sensitized WT mice demonstrated signifi cant increases in the Th2 cytokines IL4, IL5, and IL13 mRNA compared with saline-treated controls, and this response was markedly increased in OVA-treated ATF3-null mice ( Fig. 3 A ) . Signifi cant levels of secreted IL4, IL5, and IL13 were found in the BAL fl uid of OVA-treated WT mice when compared with a saline control group, and these levels were signifi cantly increased in the BAL fl uid of OVA-treated ATF3-null mice ( Fig. 3 B ) . No signifi cant change in gene expression of the Th1 cytokine IFN-␥ or the Th1-inducing cytokine IL12 was seen in either WT or ATF3-null mice after OVA treatment compared with saline controls (unpublished data).
Interestingly, there was no signifi cant diff erence in the levels of OVA-specifi c IgE and IgG1 between WT and ATF3-null mice ( Fig. 4, A and B ). In contrast, the level of OVAspecifi c IgG2a, a serum Ig isoform typical of Th1 responses, was dramatically reduced in ATF3-null mice ( Fig. 4 C ) .
ATF3 expression in T lymphocytes
We determined ATF3 mRNA levels in CD4 + lymphocytes because these cells are the major source of IL4, IL5, and IL13 ( 6 ) . Baseline transcription of ATF3 was signifi cantly higher in splenic CD4 + T cells cultured under Th2 conditions. However, TCR ligation (anti-CD3/anti-CD28) dramatically increased ATF3 expression under Th0 conditions, whereas it was not increased under Th1 conditions ( Fig. 5 A ) . Therefore, ATF3 expression in CD4 + lymphocytes is regulated both by the cytokine environment and by TCR ligation, and the eff ect is much more pronounced under Th2 conditions. with ovalbumin (OVA), increased levels of ATF3 were seen in the infl ammatory cell infi ltrate, smooth muscle layer, and around blood vessels. Interestingly, ATF3 staining of epithelium remained predominantly cytosolic, whereas infl ammatory cells showed strong nuclear localization ( Fig. 1 C ) . No ATF3 was detected in tissue from ATF3-null animals by PCR, Western blot, or immunostaining.
Role of ATF3 in lung function and allergen-induced infl ammatory responses
The role of ATF3 in regulating the asthmatic response was explored in OVA-sensitized and -challenged WT and ATF3-null mice. Lung resistance (R L ), as a measure of airway hyperreactivity, was assessed using aerosolized methacholine and invasive plethysmography. Baseline airway resistance was not signifi cantly diff erent between WT and ATF3-null mice (WT-saline, 1.17 ± 0.05; WT-OVA, 1.36 ± 0.03; ATF3-saline, Our ChIP experiments demonstrated that Junb was recruited to a site in close apposition to the ATF3 binding site in the target promoters ( Fig. 6 B ) , whereas c-Fos, Fos B, Fra-1, and Fra-2 were not (not depicted).
ATF3 regulates histone acetylation at the IL4, IL5, and IL13 promoters TF and cofactors act together to produce sustained gene transcription via modifi cation to histone structure that enhances TF accessibility ( 14 ) . ATF3 may also be involved in this process, as we have previously shown ATF3-related HDAC1 binding and associated histone deacetylation at H3 and H4 residues. Such modifi cations, in the main, are involved with transcriptional inhibition. We thus investigated histone acetylation in the IL4, IL5, and IL13 promoters in WT and ATF3-null CD4 + lymphocytes. In these studies, naive CD4 cells were cultured under Th2 conditions and then processed for ChIP. WT cells showed signifi cant H4 acetylation at the IL4, IL5, and IL13 promoters, whereas cells from ATF3-null mice showed an increase in histone acetylation at the IL4, IL5, and IL13 promoters ( Fig. 6 B ) .
ATF3 inhibits Th2 cytokine production in CD4 + T cells
OVA-sensitized CD4 + T cells from the BAL fl uid of ATF3-null mice had increased capacity to produce IL4, IL5, and IL13 compared with their WT counterparts ( Fig. 5 B ) . This was paralleled by increased cytokine production after OVA peptide stimulation ( Fig. 5 C ) . IL4, IL5, and IL13 secretion was also increased as determined by ELISA (unpublished data).
ATF3 binds to the IL4, IL5, and IL13 promoters in Th2 lymphocytes
We used MotifMogul ( 12 ) to predict ATF3 binding sites in the IL4, IL5, and IL13 promoters and identifi ed a single site with a high degree of confi dence in each promoter. These predictions were validated by chromatin immunoprecipitation (ChIP; Fig. 6 A ) . Additional experiments demonstrated that treatment of mice with the OVA peptide further increased ATF3 binding to the IL4, IL5, and IL13 promoters in CD4 + lymphocytes ( Fig. 6 A ) . These results indicate that IL4, IL5, and IL13 are direct binding targets of ATF3. Multiple AP1 and NFAT sites have been identifi ed in the Th2 cytokine locus and these are thought to coordinate transcription. ATF3 is activated in response to allergen challenge in the lungs of WT mice and contributes to the regulation of the Th2 cytokines IL4, IL5 and IL13, as well as many CCL chemokine genes that contribute signifi cantly to immune cell infl ux into the lung ( 15 ) . These increased cytokine levels can account for some of the key eff ects on the asthma phenotype seen in these mice. IL13 induces diff erentiation of goblet cells and secretion of mucin in the airways of mice after allergen challenge ( 18 ) . IL4 induces typical Th2 responses, including airway goblet cell metaplasia in a mouse asthma model ( 19 ) . IL5 promotes growth and maturation of eosinophil precursors and stimulates chemotaxis of mature eosinophils, prolonging their survival in allergic infl ammatory tissue sites by inhibition of apoptosis ( 20 ) .
Similar levels of OVA-specifi c IgE and IgG1 were induced in ATF3-null mice, indicating that they are competent in their ability to generate OVA-specifi c T cell responses and
Chemokine gene induction
Previous studies identifi ed chemokines as particularly important for cellular infl ux into the asthmatic lung ( 15, 16 ) . Consistent with this observation, there was a dramatic increase in several CCL chemokines, CCL2, 7, 8, and 11, in the lungs of OVA-sensitized/challenged ATF3-null mice when compared with their WT counterparts ( Fig. 7 A ) . CCL11 is the eosinophil-specifi c chemokine, eotaxin 1. In addition, other chemokines, including CXCL1, 2, and 5 are also highly up-regulated in the lungs of OVA-treated ATF3-null mice ( Fig. 7 B ) .
DISCUSSION
ATF3 is a member of the CREB/ATF family of BZip TFs that participate in a wide variety of biological phenomena including development, memory, and apoptosis ( 17 ) . We recently demonstrated that ATF3 is a negative regulator of TLR4-induced infl ammation ( 12 ), and we show in this paper that it signifi cantly dampens the development of allergic airway infl ammation. Our observations provide a clear link between severe asthmatic infl ammation and airway disease with the defect in transcriptional control mediated by the TF ATF3. cytes and that ATF3 binds to the Th2 cytokine promoters in close proximity to the AP-1 family TF, Junb. Junb has previously been shown to be necessary for the induction of IL4, IL5, and IL13 ( 23, 24 ) . Previous work indicates that ATF3 can physically interact with many AP-1 family members including Junb ( 25 ) . Thus, in Th2-skewed CD4 lymphocytes, ATF3 and Junb function in a feed-forward loop.
The selective allergen-induced production of Th2 cytokines and chemokines in association with diminished IFN-␥ production is a hallmark of the asthmatic response ( 26 ) . Th2 skewing has been mechanistically linked to changes in chromatin structure ( 6 ). Our previous observations demonstrating changes in chromatin structure after regulated binding of ATF3 and HDAC1 ( 12 ) suggest a possible mechanism for Th2 cytokine regulation by this TF.
The promoters of IL4 and IL13 share similar cis-regulatory elements within 500 bp of the transcription start site (TSS) that bind multiple TFs, particularly NFAT and AP-1 (Junb), which strongly synergize to induce transcription ( 27 ) .
undergo Ig isotype switching, although this is not enhanced despite increased Th2 cytokine production. It has been previously shown that IL4, through the induction of the TF STAT6, directs the transactivation of the C and C ␥ 1 promoters ( 21 ). Thus, ATF3 is not absolutely required for IgE and IgG1 expression, nor does it appear to play a role in dampening IgE production. The diminished OVA-specifi c IgG2a in ATF3-null mice are interesting, as IFN-␥ regulation of the transcription factor TBX21 (T-bet) in B-lymphocytes controls IgG class switching to IgG2a ( 22 ) . As IFN-␥ levels were undetectable in the BAL of ATF3-null mice (unpublished data), it is possible that the severe Th2 skewing in the ATF3-null animals accounts for this stark phenomenon. However, direct induction of T-bet transcription by ATF3 cannot be ruled out and will require further investigation.
We previously identifi ed ATF3 as a component of NF-B -containing transcriptional complexes in LPS-triggered macrophages. In this study, we show that ATF3 functions in AP-1 -containing complexes in Th2-skewed CD4 lympho- lung tissue ( 32 ) . IL13 is known to induce chemokine expression, a mechanism that was only partly dependent on STAT6 expression ( 33, 34 ) . Macrophages are signifi cant producers of lung chemokines and can respond to IL13 through PPAR receptor signaling pathway, which may explain this phenomenon ( 35 ) . Conversely, ATF3 may play a direct regulatory role in controlling chemokine expression, as has been previously shown for RANTES ( 36 ) and CCL4 ( 37 ) . Like the Th2 cytokine locus, CCL and CXCL chemokines are also clustered on mouse chromosomes 11 and 5, respectively ( 38 ) . Our data showing the enhanced up-regulation of these clustered CCL chemokines defi ne a potential mechanism to explain the pronounced infl ammatory cell infi ltrate in ATF3-null mice leading to asthmatic exacerbation. Given the complex interplay between diverse cell types, signaling pathways, and cis-regulatory regions contributing to the exacerbated chemokine profi les seen in the lungs of ATF3-null mice, elucidation of this mechanism will require more in-depth and cell-specifi c examination.
In conclusion, ATF3-null mice generate a complete asthmalike phenotype, including airway infl ammation, remodeling, and resulting hyperresponsiveness, and a lack of responsiveness from the ATF3 pathway confers susceptibility to severe allergic disease.
MATERIALS AND METHODS
Animals. C57/Bl6 mice were purchased from Charles River Laboratories. ATF3 Ϫ / Ϫ mice were a gift from T. Hai (Ohio State University, Columbus, OH).
These NFAT/AP-1 regions are called P sites and act via cooperative binding to form a higher order transcriptional complex. We identifi ed ATF3 recruitment to the essential P2 region of the IL4 promoter ( 28 ). Importantly, Type I HDAC (HDAC1, 2, or 3) activity has been identifi ed in this region of the promoter ( 29 ) . Therefore, ATF3-mediated HDAC1 recruitment and resulting eff ects on histone acetylation levels off er a mechanistic explanation for this observation. Significantly less is known about regulatory regions of the IL13 promoter, although the ATF3 binding site is also, amid P sites, closely opposed to the TSS ( 30 ) . These similarities in promoter binding site architecture and histone regulation may lead to the shared expression kinetics of IL4 and IL13.
Transcriptional control of the IL5 promoter is less completely described. There are four cis elements necessary for full transcriptional activation ( 31 ) . The fi rst of these, termed IL5A, is found Ϫ 940 bp from the TSS and is within ‫ف‬ 40 bp of the ATF3 binding site. This is the upstream enhancer region of IL5, and deletion of these sites inhibits transcription by ‫ف‬ 50% ( 31 ). As ATF3 can recruit HDAC activity to these sites, resulting in condensed chromatin and inhibited gene transcription, this may be a necessary regulatory switch in Th2 cytokine production.
A signifi cant hallmark of asthma is accumulation of eosinophils, neutrophils, lymphocytes, and macrophages in the lung, a process which is highly dependent on chemokines. This cellular infl ux is directly proportional to disease severity. Many cell types contribute to chemokine mRNA profi les seen in asthmatic BAL. The right lung was isolated with a suture and lavaged with one wash of 1 ml of saline. The total number of leukocytes per 50-μ l aliquot was determined after methylene blue staining. The remaining BAL fl uid was centrifuged at 200 g for 5 min at 4 ° C, and supernatants were stored at Ϫ 80 ° C until assay of cytokine protein levels. The remaining cells were cytospun onto glass slides. Cell diff erentials were determined by Diff -Quik staining (Siemens).
Lung histology. The left lung tissue was fi xed in 10% neutral buff ered formalin at 20 ° C for 15 h. The tissues were embedded in paraffi n and cut into 5-μ m sections. A minimum of 10 fi elds was randomly examined by light microscopy by a blinded observer.
Assay of T lymphocytes. Spleens were mechanically dissociated in cold PBS, followed by depletion of erythrocytes with lysis buff er containing NH 4 Cl. Naive CD4 + T cells were isolated (either from spleen cells or BAL fl uid) by negative selection with (Miltenyi Biotec). Purity of CD4 + cell populations was > 98% as determined by fl ow cytometry. Th cell cultures were established as previously described ( 40 ) . In brief, CD4 + cells (10 6 /well) were plated in RPMI 1640 (Invitrogen) containing 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin, 100 μ g/ml streptomycin, 10 mM Hepes (Invitrogen), and 20 μ M 2-ME (Sigma-Aldrich) were incubated at 37 ° C in a 5% CO 2 atmosphere and stimulated for 72 h in 10 μ g/ml of anti -mouse CD3 -and 10 μ g/ml of anti -mouse CD28 -coated 24-well plates (BD Biosciences). In addition, 10 ng/ml IL4 and 10 μ g/ml of anti -IFN-␥ antibody (Th2 conditions) or 5 ng/ml IL12 plus 10 μ g/ml of anti-IL4 (Th1 conditions) or 20 μ g/ml of anti-IL4, 20 μ g/ml of anti-IL12, and 10 μ g/ml of anti -IFN-␥ (Thneutral [Th0] conditions). After 6 d, T cells were washed in PBS and then reseeded on CD3/CD28-coated plates for the times indicated. For OVAspecifi c activation, CD4 + cells were incubated with 500 μ g/ml OVA (Thermo Fisher Scientifi c) for 5 d. Cytokine analysis for IL4, IL5, and IL13 were performed by ELISPOT (BD Biosciences), according to the manufacturer ' s protocol.
Real-time PCR analysis. Total RNA was prepared from lung homogenates using Trizol reagent (Invitrogen) according to the manufacturer ' s protocol. cDNA was produced with MMLV Reverse transcription (Promega), according to the manufacturer ' s recommendations, and primed with oligo d(T) (Promega). Quantitative real-time PCR was performed on an ABI 7700 (Applied Biosystems) using TaqMan Universal PCR Master Mix (Applied Biosystems). Commercially available primer/probe pairs (Applied Biosystems) were used at a fi nal concentration of 0.9 mM. The PCR program was as follows: 50 ° C for 2 min and 95 ° C for 10 min (95 ° C for 15 s and 60 ° C for 1 min) for 40 cycles. All data were normalized to EF1-␣ expression in the same cDNA set.
Western blot. Lung homogenates were dissociated in 500 μ l RIPA buff er (PBS and 1% NP-40). 10 μ g of protein from each sample was mixed with Laemmli loading buff er. Samples were separated on a 4 -20% gradient SDS-PAGE gel and transferred onto a PVDF membrane (Bio-Rad Laboratories). The membrane was then incubated with primary antibodies for 1 h at room temperature. The secondary antibody, horseradish peroxidase -conjugated goat anti -rabbit IgG (1/5,000; AbD Serotec) was incubated for 1 h at room temperature. Labeling was detected by chemiluminescence by addition of SuperSignal substrate solution (Thermo Fisher Scientifi c).
ChIP. After stimulation, lymphocytes were fi xed in formaldehyde and ChIP assay was performed, as previously described, with rabbit anti-ATF3 antibody (C terminus; Santa Cruz Biotechnology, Inc.), Anti-Junb (Santa Cruz Biotechnology, Inc.), Anti-c-Fos (Pan; Santa Cruz Biotechnology, Inc.), and anti-acetylated histone-H4 (Millipore) ( 12 ) . Quantitative real-time PCR was performed using primers specifi c for the predicted ATF3 binding region of IL4, IL5, and IL13 with TaqMan Universal PCR Master Mix (Applied Biosystems) and SYBR green detection. IL4 forward, 5 Ј -GGTCTAGGAT-GCGAGAAGGT-3 Ј ; and reverse, 5 Ј -GCCTAGCTGCTTCCTGC-TAT-3 Ј . IL5 forward, 5 Ј -CGAACCTGCTGTGTGTGACA-3 Ј ; and reverse, All animal use procedures were approved by the University of Washington Animal Care Committee (Seattle, WA).
Allergen sensitization and challenge. Mice were sensitized and later challenged with OVA (Thermo Fisher Scientifi c) as previously described ( 39 ) . All solutions, including OVA, were negative when tested for LPS contamination by the Limulus assay (sensitivity > 0.01 ng/ml LPS; Sigma-Aldrich). Mice were immunized with 100 μ g OVA complexed with aluminum hydroxide in a 0.2-ml volume, administered by i.p. injection on days 0 and 14. Mice were anesthetized i.p. with 130 mg/kg ketamine and 8.8 mg/kg xylazine in normal saline before receiving an intranasal dose of 100 μ g OVA (0.05 ml of 2 mg/ml) on day 14 and 50 μ g OVA (0.05 ml of 1 mg/ml) on days 26, 27, and 28. The control group received 0.2 ml of normal saline with alum i.p. on days 0 and 14 and 0.05 ml saline without alum intranasally on days 14, 26, 27, and 28.
Pulmonary function testing. On day 29, invasive pulmonary mechanics were measured in mice in response to methacholine in the same manner as previously described ( 39 ) . The mice, ventilated with a tidal volume of 200 μ l and respiratory rate of 120 breaths per minute using a MiniVent ventilator for mice (Harvard Bioscience), received aerosolized solutions of methacholine (0, 3.125, 6.25, 12.5, 25, and 50 mg/ml in normal saline) via an AER 1021 nebulizer aerosol system (Buxco Research Systems) with 2.5 -4-μ m particle size generated by NEB0126 nebulizer head (Nektar). A commercial plethysmography system (PLY4111 plethysmograph, MAX II amplifi er and pressure transducer system, and Biosystem XA software; Buxco Research Systems) was used to determine R L as calculated from measures of pressure and fl ow and expressed as cm H 2 O/ml/s). 
